



MARYLAND MEDICAID PHARMACY PROGRAM

No. 140
December 18, 2013

ADVISORY

*In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) **Maryland Medicaid Pharmacy Program (MMPP)** has developed the **Maryland Medicaid Pharmacy Program Advisory**. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MMPP representative at 410-767-1455.*

Brand Cymbalta® Is To Be Dispensed (DAW6) Over Its Generic

The purpose of this Advisory is to alert you that **effective Thursday, December 19, 2013**, all prescriptions for **Cymbalta®** are to be dispensed using the branded product instead of the generic (duloxetine delayed-release capsules). Claims for Cymbalta® must be submitted with **DAW 6** and will be priced appropriately. Claims for Cymbalta® with any other DAW code will reject. A DHMH Medwatch form will not be required, however since Cymbalta is currently non-preferred, a PDL Prior Authorization request may be required. Effective January 1, 2014, Cymbalta® will become a preferred drug on the Preferred Drug List (PDL) and will not require a PDL Prior Authorization.

If any problems are encountered during the on-line claim adjudication, please contact the Xerox 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if the member has primary insurance).